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Abstract 
A randomized controlled trial (RCT) is a prospective, comparative, quantitative 
study/experiment performed under controlled conditions with random allocation of 
interventions to comparison groups. The RCT is the most rigorous and robust research method 
of determining whether a cause-effect relationship exists between an intervention and an 
outcome. High quality evidence can be generated by performing an RCT when evaluating the 
effectiveness and safety of an intervention. Furthermore, RCTs yield themselves well to 
systematic review and meta-analysis providing a solid base for synthesizing evidence generated 
by such studies. Evidence-based clinical practice improves patient outcomes, safety, and is 
generally cost-effective. Therefore, RCTs are becoming increasingly popular in all areas of 
clinical medicine including perinatology. However, designing and conducting an RCT, analyzing 
data, interpreting findings and disseminating results can be challenging as there are several 
practicalities to be considered. In this review, we provide a simple descriptive guidance on 
planning, conducting, analyzing and reporting RCTs.  
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Abbreviations 
RCT  randomized controlled trial 
 
Key message 
Appropriately planned and rigorously conducted RCTs remain the most robust research method 
available to find the real effect of an intervention, but a biased RCT can lead to adoption of a 
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wasteful intervention, and may even harm patients. This manuscript provides a step-by-step 
guide to planning, conducting, analyzing and reporting RCTs.  
 
Introduction 
Evidence from randomized controlled trials (RCTs) is considered to be at the top of the evidence 
pyramid. It is recommended that clinical practice decisions are based on evidence emanating 
from well-conducted RCTs when available (1). Following the pioneering works by James Lind 
for scurvy (2) and Sir Bradford-Hill for the treatment of tuberculosis (3,4), gathering of 
evidence for clinical practice based on RCTs has become increasingly common. This document 
will review the need and scope for RCT evidence in perinatology. It will provide a practical 
guide to researchers wanting to pursue this exciting field of research.  
 
Why RCTs?  
A fundamental question that any researcher may ask is, why is it that evidence based on RCTs is 
considered to be of the highest quality. The main reason for this is that evidence based on 
observational data is prone to bias. Bias is defined as the systematic tendency of any factors 
associated with the design, conduct, analysis, evaluation and interpretation of the results of a 
study to make the estimate of the effect of a treatment or intervention deviate from its true 
value. If two or more groups are being compared in an observational study, there often are 
systematic differences between the groups, so much so that the outcome of the groups may be 
different because of these differences rather than actual exposure or intervention. This is 
known as confounding. The only way to eliminate these differences is to allocate each individual 
to one or the other intervention at random. Therefore, the probability of any individual 
receiving one intervention or the other is decided solely by chance. In this scenario, if sample 
size is sufficient, all the factors influential in the outcome are likely to be distributed equally 
between the groups, because the allocation was at random. Therefore, any difference in the 
observed outcome between the groups is likely to be due to the intervention rather than any 
other factors. Although randomization is the best way to minimize the risk of confounding by 
unmeasured factors, RCTs could still be confounded. A recent article by Howards provides 
several suggestions on how to address confounding (5).  
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What questions are suitable for an RCT?   
An RCT is a study design that is generally used in experiments testing the effectiveness and/or 
safety of one or more interventions. The intervention being tested is allocated to two or more 
study groups that are followed prospectively, outcomes of interest are recorded, and 
comparisons are made between intervention and control groups. The control group may receive 
no intervention, a standard treatment, or a placebo. The intervention can be therapeutic or 
preventive and doesn´t necessarily have to be a pharmaceutical agent or a surgical intervention.  
 
RCTs are suitable both for preclinical and clinical research. There should be sufficient 
uncertainty about the utility of an intervention. This is referred to as equipoise. For clinical 
trials, the proposed intervention is sometimes based on logic, but mostly on data obtained from 
in vitro laboratory studies, animal experiments or preliminary serendipitous/ planned 
observation in an uncontrolled setting. Observational (case-control or cohort) studies may 
suggest benefit of an intervention, but they are prone to bias. Important and relevant gaps in the 
scientific knowledge sometimes come to light in the process of developing guidelines, and such 
gaps need to be addressed by producing robust evidence.  
 
The question to be answered by RCT design should also be safe from participants´ point of view. 
Investigators cannot subject participants to any undue risk/harm. For clinical trials, it can be 
argued that it is unethical to expose participants to any risk or burden if the research lacks 
social value (6). There are conditions/situations or statuses for which there is unlikely going to 
be an RCT; for example, the effectiveness of a parachute in preventing death while sky-diving. 
One needs to be practical in understanding such dilemmas and not be blind-sided by 
proponents of RCTs (7).  Finally, the research question also needs to be ethically appropriate to 
be answered in an RCT setting. Experiments conducted on human subjects before or during 
World War II provide striking reminders of the importance of obtaining voluntary informed 
consent from participants and ensuring their well-being in the design of RCTs (8). What is 
considered ethical may change with time and accumulation of knowledge. As an example, 
clinical trials of intravenous administration of alcohol to pregnant women as a tocolytic agent to 
halt preterm labor were performed during 1960s to late 1980s (9,10). However, administering 
alcohol to pregnant women is no longer ethical in light of its harmful effects on the mother and 
developing fetus.  
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RCTs are equally useful to study effectiveness and/or safety of diagnostic and screening tests. 
However, RCTs are not suitable for investigating etiology or natural history of disease. 
Outcomes that are extremely rare or take a very long time to develop are also impractical to 
study using an RCT. 
 
How should an RCT be designed? 
Detailed guidance on planning of clinical trials is available (11), and should be followed. Here, 
we will only consider the basic principles. The first step is to assess if a RCT is the best research 
design for the research question. Then, it is necessary to confirm that the question has not 
already been answered by an appropriately powered (please see later) RCT. This requires a 
systematic literature search.  
 
Research question formulation 
A hypothesis has to be formed for a research question to be answered using an RCT. The 
hypothesis has to be precise. The key components of a sound research question should include: 
P (population of interest), I (Intervention to be studied), C (comparator intervention), O 
(outcomes to be evaluated) and T (is there a time duration for intervention/outcome 
ascertainment time). Adequate time needs to be devoted to converting a “free form” question 
arising from a clinical or non-clinical context to convert it into a properly answerable “PICOT” 
format question. This is best demonstrated using an example of tranexamic acid that is shown 
to reduce blood loss during cesarean section (12, 13). To address the free flowing research 
question ‘Does administration of tranexamic acid prevent post-partum hemorrhage?’, 
investigators need to convert this into an answerable and specific question. The population 
needs to be defined clearly, such as whether one would investigate women delivering vaginally, 
by cesarean section (which could also be emergency or elective), or both. Next, the intervention 
requires specific stipulation as to how much, how frequently, what dose, what time and what 
route would be used for administering tranexamic acid. For a comparator, it needs to be clearly 
outlined whether this intervention is compared to placebo or no treatment or any other 
currently used measures to prevent PPH. The outcome also needs to be clearly defined with 
regard to what definition of PPH will be used for the trial (for example, blood loss >500ml or 
>1000ml). As the outcome of interest here occurs within a fairly short time frame of completion 
of intervention, the time component may not be very relevant to this question. Thus, a refined 
form of the question may look like this: “Does 1.0 gram of intravenous tranexamic acid given 4 
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hours prior to elective cesarean section compared to placebo reduce post-partum hemorrhage 
diagnosed as estimated blood loss of >500ml within 24 hours of birth?”  
 
As evident form the above exercise, an ample amount of time must be devoted to carefully 
honing the research question. This should result in a very well-defined, clear, feasible, specific, 
measurable, ethical and clinically important question before one initiates the experiment. 
  
How should an RCT be conducted? 
Once a research question is generated, the next step in the conduct of an RCT will be to clearly 
define the target population, inclusion and exclusion criteria, process of randomization, 
allocation, blinding of intervention, treatment and control delivery, outcomes assessment, 
definitions of outcomes, sample size required, ethical requirements, consent process and, 
finally, data management. These topics should be written as a well-defined protocol. The 
protocol should be reviewed and approved by an independent ethics committee prior to 
starting the trial. For clinical trials, it is now obligatory that protocols are registered with a 
publicly available trial registry before recruiting any participants to the trial. Apart from 
promoting transparency, most journals have this as a mandatory requirement and would not 
publish the results of an RCT unless trial registration details are provided. Retrospective 
registration may not be acceptable. Some medical journals also accept RCT protocols for 
publication. This is to make sure that protocols are not altered as a result of trial results. It also 
helps to ensure that negative trials are not left unpublished. Nevertheless, only two-thirds of 
RCTs in women’s health published in 2015 were prospectively registered, and more than half 
did not achieve the planned sample size (14). However, this is expected to change in future. 
Moreover, the International Committee of Medical Journal Editors (ICMJE) has recently 
suggested that clinical trials that will begin enrolling participants on or after January 1, 2019 
must include a data sharing plan when registering the trial (15). 
 
An independent data monitoring committee is usually established to periodically oversee the 
progress of a clinical trial, safety data, and critical efficacy variables and to recommend to the 
sponsor (funder) whether to continue, modify or terminate a trial. 
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The key components of design of an RCT are highlighted below:  
Random allocation 
Each of the eligible participants should have an equal chance to be allocated the intervention or 
not. The simplest way of achieving this is by parallel group design, in which each group of 
participants is exposed to only one of the study interventions. In a crossover design, all the trial 
participants receive both interventions in a sequential manner and only the order of 
intervention is randomly assigned. In this way, each participant serves as his/her own control, 
thereby eliminating individual participant differences. However, this design is more vulnerable 
to drop out and attrition. If a particular baseline characteristic is of such fundamental 
importance as to have a big influence on the outcome, it can be taken into account at 
randomization. Participants with or without that baseline characteristic are randomized 
separately (stratified randomization). Block randomization is used in order to maintain a 
balance between the intervention group and control, so that the numbers are not too dissimilar, 
which could rarely happen by chance. Cluster randomization can be used when randomization 
of individual participants is not feasible/practical, in which case hospitals, clinics, geographic 
areas etc. can be used as units for the allocation of intervention or control groups. Generation of 
random sequence should be done by some independent personnel, usually a statistician, who is 
not going to be involved in the conduct of the RCT. The access to this sequence should be 
restricted to only a few individuals who absolutely need to have access (such as the pharmacist 
who will be preparing the medication) and not the investigators or personnel involved in 
ascertaining outcome. The sequence should be opened by this individual only on a case by case 
basis and specified sequence should be followed. 
 
Allocation concealment 
One of the key components of an RCT is allocation concealment. This means that neither front 
line care providers, investigators or participants are aware of whether the next eligible 
participant will be receiving treatment or control intervention. This should be masked until the 
time participants are ready to receive intervention. By this virtue, unnecessary adjustments in 
whether to enrol a participant or not (such as after knowing that the prognosis is not good and 
the patient is randomized to an experimental treatment, the investigator changes her/his mind 
and decides not include the participant in the study) can be avoided. This is very important in 
situations when blinding of intervention is not possible. 
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Blinding 
The focus of conducting an RCT is elimination of bias. Unconscious information bias may be 
introduced if the investigators or participants are aware of who is getting the intervention and 
who is not. The procedure of blinding the participants (single blind) or both investigators and 
participants (double blind) helps to eliminate this unconscious information bias. Whenever 
possible, blinding should be used in an RCT. It is not always possible to blind either the 
participants or investigators due to the nature of the RCT. For example, Jozwiac et al (16) 
conducted an RCT comparing vaginal prostaglandins with trans-cervical balloon catheter for 
induction of labor (PROBAAT study). It was possible to randomize participants to the two types 
of interventions, but it was not possible to blind the participant or the investigator. Therefore, 
this trial was conducted as an open-label RCT.  
 
Conduct 
An RCT can be conducted at a single site or at multiple sites. RCTs conducted according to a 
single protocol but at more than one site are referred to as a multi-center trials. Including 
several sites has the advantage of reaching the required sample size within a shorter time and 
may also improve generalizability of findings.  
 
The main premise of conducting an RCT is that the participants should be treated exactly the 
same way in both arms except for the intervention/control treatment. All other procedures of 
treatment, diagnosis, investigations, alterations etc. should follow the routine process and no 
undue advantage or testing should be performed on patients in the trial. These data should be 
collected to identify issues of contaminations, cross over of intervention and co-interventions.  
 
Outcome ascertainment 
The pre-specified primary and secondary outcomes should be collected by independent 
observers who are unaware of the allocation and treatment arm of participants. As far as 
possible, it is advisable that objective measures are used for ascertaining outcome so that 
personal bias on the part of the collector does not come into play. This is particularly important 
when the intervention cannot be masked (such as scar of surgery). It is also important that the 
outcome is collected in all randomized patients. The number of patients with missing outcome 
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data should be minimized as much as possible. A high rate of attrition will lead to reduced 
confidence in the results and may lead to biased estimates. 
 
Sample size  
One would always like to conduct a study which has adequate sample size and power so that the 
conclusions generated from the experiment can be applied to the broader population with 
ample confidence. The required sample size to test a hypothesis is governed by the effect size 
(17). In a superiority trial, one would like to detect difference in the effect of intervention versus 
placebo, which is a minimum clinically important difference (MCID), that is required to detect 
between two groups and convince users of the information to utilize the intervention. This 
number is usually derived from previous experiments/observations, previous trials or by 
consensus opinion. In general, the more widely the two groups are separated from each other 
and the smaller the variability in each group, the fewer participants are necessary in each group 
to show that the difference is unlikely to be due to chance and more likely to be due to the 
intervention. The inclusion of too few patients in a study increases the risk that a significant 
treatment benefit will not be shown, even if such an effect exists (a type 2 error). The details of 
actual calculations are beyond the scope of this manuscript but published literature on this 
topic is quite abundant and standard formulas are available to calculate sample size (18,19). 
Expert statistical help should be sought when needed. However, some key information should 
be gathered before seeking statistical help. First, one needs to know the baseline estimate of 
outcome rate in the placebo/control arm, i.e. how many patients are expected to benefit from 
the control intervention. Second, it is important to have an expected estimate as to what 
percentage of patients are expected to benefit from the intervention. This is where one needs to 
be careful to not overestimate the benefit (as this will need lower sample size) or to 
underestimate the benefit (as one may end up experimenting on more patients than necessary). 
Two more aspects that must be kept in mind are:  how much  type 1 and type 2 errors are we 
willing to accept before rejecting the null hypothesis (as described below). 
 
Power of a study 
If there are significant differences in the primary outcome between the two groups, one can 
conclude that the difference is likely to be due to the intervention. Typically, the difference is 
thought to be ‘significant’ if the probability of this difference arising solely due to chance is less 
than 0.05. This is the well-known probability (p)-value. Therefore, the chance that a difference 
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will be found even if there is no real difference is 1:20 (0.05). This is known as a type 1 error, 
and is usually fixed at 0.05 due to convention.  However, it is not necessary to fix this at 0.05, 
and other levels of significance (0.01 or 0.005) may be chosen. It is possible that a significant 
difference may not be observed even if this is present. The chance that the study will be able to 
demonstrate a significant difference if it is present, is known as the power of the study. By 
convention it is fixed at 0.8 to 0.95 level (80-95%). Inability to demonstrate a significant 
difference even when one does exist, is known as a type 2 error. The probability of type 2 error 
is conventionally set at 0.2 to 0.05. With these four values, it will be easy for a statistician to 
calculate sample size in an experiment where effect size is measured in proportion. If the effect 
size is measured on continuous variable (such as difference in blood pressure) than one would 
need the mean and standard deviation of variable in each group in addition to type 1 and 2 
error values to calculate the sample size. This provides adequate information for most routine 
types of RCTs. For different and complicated statistical parameters to be evaluated in an RCT, it 
is advisable to consult an experienced statistician before the designing the experiment, as 
prohibitive sample size may jeopardize research efforts significantly. RCTs can be designed and 
conducted to evaluate the superiority, equivalence or non-inferiority of an intervention 
compared to another, and power calculations are different for these different types of RCTs. 
Power calculations may be based on simulations performed by a statistician, the details of 
which are beyond the scope of this review. 
 
Trial phases 
Clinical trials evaluating safety and efficacy of pharmaceutical agents generally have to go 
through a series of studies before they can be used in clinical practice. There are four sequential 
phases of clinical trial that have the objective of: studying human pharmacology of the agent 
(phase-I); exploring therapeutic potential (phase-II); confirming therapeutic effect (phase-III); 
and evaluating it for therapeutic use (phase –IV). Phase-I trials are conducted in a small number 
of healthy subjects (20-80) to determine the absorption, distribution, metabolism and toxicity of 
a new drug in humans for first time. Phase-II trials are designed to estimate dose and test the 
safety and therapeutic efficacy in a slightly larger population (100-300) afflicted with the 
condition for which the drug was developed. Phase-III is a definitive study of efficacy of the drug 
after sample size estimation for proper evaluation. Data on side effects are collected 
meticulously. Phase-IV trials are post marketing studies after a drug has been approved by a 
regulatory body such as the Food and Drug Administration in the USA or the European 
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Medicines Agency in Europe. Such trials provide additional information including the benefits, 
optimal dose, effectiveness and adverse events of the drug in different patient populations etc.   
 
Improving generalizability 
Generalizability should be considered as a very important criterion in designing an RCT. The 
answer provided by an RCT is applicable to the patient population similar to that used in the 
trial. Extrapolating it to other patients is not strictly valid. Therefore, the inclusion criteria 
should be as wide as is practically possible, while at the same time maintaining scientific rigor. 
None of the afore-mentioned steps should be so strict that once the RCT is over, replication of 
the intervention is impossible in a practical setting. The process of administering intervention 
to a group of subjects should be relatively easy, and collection of outcome data should also not 
be too onerous. For example, the investigators of WOMAN trial (13) used a clinical definition of 
post-partum hemorrhage, and supplemented it with a quantitative estimation of blood loss: 
>500 ml for vaginal births, and >1000 ml for operative deliveries. This implied that the trial 
result was valid both for spontaneous and operative delivery.  
 
Interim analysis 
RCTs are designed with an anticipated incidence of the primary outcome in the control arm. The 
observed incidence may be lower, making the trial underpowered, or higher, making the trial 
unnecessarily prolonged. Interim analysis is a useful way to make sure that the observed 
incidence is not too different from the expected incidence. However, interim analyses should be 
pre-planned and stated in the protocol.  Analysis should be performed by an independent 
statistician blinded to the identity of either group. Interim analysis may sometimes show that 
differences in the two groups are large and show a clear advantage of the intervention. In this 
case, continuing the trial is unethical because the control group will be denied the clearly 
superior alternative. On the other hand, early discontinuation may be advisable if the incidence 
of primary outcome in the control is far too low and the revised sample size is deemed to be 
unfeasible. Upward revision of the required sample size may result from the interim analysis as 
was the case in the WOMAN trial (13). When event rates are lower than anticipated or 
variability is larger than expected, methods for sample size re-estimation are available without 
un-blinding. The observed incidence in the placebo arm of the study is often lower than 
anticipated. In the WOMAN trial, the anticipated rate of death was 3.0% in the placebo arm, but 
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the observed incidence was 1.9%. An independent data monitoring committee usually oversees 
the interim analysis.  
 
Ethical Considerations 
Rigorous ethical principles must be applied to all RCTs involving experiments on animals, 
humans or human biological material (20). Evaluation of risk and benefit to the participants and 
society, obtaining ethical approval, and informed consent are crucial. Before planning and 
conducting an RCT, it must be considered and evaluated whether it is ethical to use 
randomization to allocate participants to an intervention group. Where there is previous 
evidence showing superiority of an intervention over that of doing nothing, an RCT using a 
placebo (or doing nothing) is unethical. For example, prior to the development of anti-retroviral 
therapy, untreated HIV infection was associated with near certain fatality. Today it is a treatable 
condition although newer, more effective treatments continue to be invented. Therefore, RCTs 
in this field comparing one drug or treatment regime against another would be ethical, but the 
use of placebo would not.  
 
Safety concerns 
As is true of medicine, participants must not be harmed by the experiment. Therefore, pre-
defined, serious, adverse events need to be reported to the sponsor and to the trial monitoring 
committee. Any complications or side effects of drugs should be reported to regulatory bodies. 
Unacceptably high frequency of adverse events in the intervention group may lead to early 
discontinuation of the trial, usually recommended by the data monitoring committee.  
 
How should an RCT be reported?  
There are guidelines for reporting on RCTs (www.consort-statement.org), which should be 
followed. Many RCTs report baseline characteristics of the two (intervention and control) 
groups. If the allocation was random, any differences between the baseline characteristics of the 
two groups must be by chance. Therefore, a comparison with statistical testing and reporting p-
values is superfluous.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
The type of comparison made between intervention and control groups is important, especially 
when efficacy of an intervention is being evaluated. Therefore, whether it is a superiority, non-
inferiority or equivalence trial should be reported. 
 
It is not uncommon that some participants do not receive the intervention allocated by the 
randomization process. The gold standard of reporting is ‘intention to treat’ analysis. Outcomes 
of all participants randomized to the intervention arm should be reported in that group even if 
some of the participants may not have received the intervention. The analysis by intention to 
treat, and according to the intervention that they actually received (per-protocol analysis) can 
rarely lead to differing results. Reporting per-protocol analysis rather than intention to treat 
analysis often results in over-estimation of the effect of intervention. Grouping participants 
according to the actual treatment received can introduce a bias, and is discouraged. The best 
strategy to guard against such a possibility is to maintain protocol violations to a minimum. 
While reporting the primary outcome, it is becoming increasingly customary to report the effect 
size (and its 95% confidence interval) rather than just the p-value, as this provides meaningful 
information about the magnitude of change. It is best to always use 2-sided p values (21). It is 
also a good practice to give the actual p-values rather than p<0.05 or “significant,” and p>0.05  
or “not significant” (21).  
 
How should RCTs be interpreted?  
An RCT is an experiment. If the difference in the primary outcome is significant at the customary 
level of p <0.05, chances are that the observed difference is real. The magnitude of the observed 
difference is also important. The magnitude may be small, but still statistically significant. In this 
case, the clinical significance is most often limited. The magnitude may be large, but still 
statistically non-significant. In this case, the study remains underpowered. Appropriate sample 
size calculations prior to embarking on the study should prevent this situation. In many cases, 
the observed difference is small, and is not statistically significant. This constitutes a negative 
trial. It does not mean that the trial has failed. When a trial is too small to detect modest 
treatment effects, it is appropriate to describe the findings as inconclusive rather than negative. 
It is a matter of great joy for the investigators when the anticipated difference is found between 
the two groups and is statistically significant. As great care has been observed in the conduct of 
the trial, the results are likely to be reproducible. However, the scientific community was 
recently shaken by reports that a troubling proportion of peer-reviewed pre-clinical studies are 
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not reproducible. New initiatives have been proposed to increase confidence in the published 
studies (21). Generalizability should also be taken into account when interpreting results. When 
applying the evidence gathered from an RCT to a clinical situation, the question to ask is ‘is my 
patient so different compared to the participants of the RCT so as to make the results of the RCT 
inapplicable?’ The evidence is valid as long as the answer to this question is ‘no’. Interpretation 
of any trial should depend not only on the primary outcome, but on the totality of the evidence 
(i.e., the primary, secondary, and safety outcomes).  
 
Conclusion 
The RCT is the most rigorous and robust research method for determining whether a cause-
effect relationship exists between an intervention and an outcome. Therefore, it is important to 
perform RCTs to generate evidence in basic, translational and clinical research and improve the 
management of our patients. However, an RCT should be conducted only if it is ethically 
feasible, economically viable and clinically worthwhile. 
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